Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: GPCR modulators - Nxera Pharma

Next Previous
Drug Profile

Research programme: GPCR modulators - Nxera Pharma

Alternative Names: allosteric modulators of metabotropic glutamate receptor (5mGluR5) - Nxera Pharma; calcitonin gene-related peptide (CGRP) modulators - Nxera Pharma; CNS disorder therapeutics - Nxera Pharma; H4 receptor antagonist - Nxera Pharma; M1/M4 agonist - Nxera Pharma; mGlus NAM - Nxera Pharma; muscarinic M1 agonists - Nxera Pharma; Orexin OX1 receptor antagonist - Nxera Pharma; Orexin OX1/OX2 dual receptor agonists; Orexin OX2 agonists - Nxera Pharma; OX-1 antagonist - Nxera Pharma

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heptares Therapeutics
  • Developer AbbVie; Medical Research Council; Nxera Pharma; Shire; Takeda; Tempero Bio
  • Class Antimigraines; Anxiolytics; Drug withdrawal therapies; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2A receptor antagonists; Calcitonin gene-related peptide antagonists; G protein-coupled receptor modulators; Histamine H4 receptor antagonists; Metabotropic glutamate receptor 5 antagonists; Metabotropic glutamate receptor 5 modulators; Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical CNS disorders
  • Research Anxiety disorders; Substance-related disorders
  • No development reported Atopic dermatitis; Autistic disorder; Cocaine-related disorders; Cognition disorders; Depressive disorders; Migraine; Obsessive-compulsive disorders; Parkinson's disease; Psychotic disorders; Sleep disorders; Unspecified

Most Recent Events

  • 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
  • 28 Apr 2023 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom
  • 01 Dec 2021 Preclinical trials in CNS disorders in United Kingdom (unspecified route) (Sosei Heptares pipeline, December 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top